Skip to content

CLINICAL TRIAL TO EFFICACY OF INJI CHOORANAM - 2 [INTERNAL], VATHA KESARI THYLAM [EXTERNAL] AND VARMA THADAVAL [EXTERNAL THERAPY] in HEMIPLEGIA.

AN OPEN NON- RANDOMIZED PHASE II CLINICAL TRIAL TO EVALUATE THE THERAPEUTIC EFFICACY OF SIDDHA SHASTRIC MEDICINE INJI CHOORANAM - 2 [INTERNAL], VATHA KESARI THYLAM [EXTERNAL] AND VARMAM THERAPY FOR THE TREATMENT OF PAKKA VAYU [HEMIPLEGIA].

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2018/05/013699
Enrollment
40
Registered
2018-05-04
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Patients suffering from Hemiplegia

Interventions

Intervention1: Inji Chooranam 2 and Vatha kesari thylam: Inji Choornam 2 - oral route twice daily varma points stimulation and varma thadaval with vatha kesari thylam Control Intervention1: NIL: NIL

Sponsors

Mathan
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 2. SEX: Both male and female. 3. Inability/ difficulty to use one side of the upper and lower limb. 4. Difficulty in speech. 5. Patient with Thrombotic or Embolic stroke. 6. Willing for admission in IPD for 48 days or willing to attend OPD regularly. 7. Patients who are willing to participate in this study with knowledge of potential risks and who are willing to sign the informed consent form. 8. Patient who are willing to give blood sample for laboratory investigation

Exclusion criteria

Exclusion criteria: 1. Patient in an acute phase of CVA. 2. Pregnant women and lactating mother. 3. Known Hypersensitivity or allergy to trial drugs. 4. Patients with other serious, advanced or terminal illness. 5. Bed sores. 6. Bladder and Bowel control lost. 7. Epilepsy. 8. Comatose and unconscious patients. 9. Patient with haemorrhagic stroke, Neoplasam, subarachanoid haemorrhage, AV malformation. 10. Dermatological issues. 11. Congenital defects -diffuse sclerosis, cerebral agenesis etc. 12. Post operative cases within 3 months [eg.CVD, etc.], Head injury.

Design outcomes

Primary

MeasureTime frame
The primary outcome will be assessed based on assessment criteria for stroke patientsTimepoint: 48 days

Secondary

MeasureTime frame
Assessment of quality of life with respect to SS-QOL. 2.Assessment of improvement in clinical signs and symptoms with respect to following of Iyama and Niyama. 3.To evaluate the clinical efficacy of the trial drug with respect to theganilai. Timepoint: 48 days

Countries

India

Contacts

Public ContactKMathan

Govt Siddha Medical College Hospital

arunapriya1995@gmail.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026